HELP (Helus Pharma) Tariff Resilience Score: 6/10 (As of Jul. 08, 2026)


HELP Helus Pharma Inc HELP
33 GF Score
Price $6.02
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Tariff Resilience Score?

Helus Pharma HELP +2.38% 33 Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus rates HELP with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,368 Biotechnology companies, Helus Pharma ranks better than 75.95% on this metric.

Helus Pharma has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Helus Pharma has Cybin Inc, a biotech firm, faces moderate tariff risks due to its reliance on international supply chains for research materials. However, the company can mitigate these risks through strategic partnerships and alternative sourcing.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Helus Pharma might have Average Resilient.

Helus Pharma  (NAS:HELP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Helus Pharma Tariff Resilience Score Related Terms

HELP vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Helus Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helus Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Helus Pharma's Tariff Resilience Score falls into.


HELP
33GF Score
Helus Pharma Inc HELP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Helus Pharma (HELP) has a Tariff Resilience Score of 6 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Helus Pharma ranks #329 out of 1368 companies in the Biotechnology industry, placing it in the top 24%.
Is Helus Pharma's Tariff Resilience Score too high?
Helus Pharma's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Helus Pharma's value of 6 is 50% above this industry median. Based on the distribution chart, Helus Pharma ranks #329 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Helus Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #329 out of 1368 companies for Tariff Resilience Score. This places Helus Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Helus Pharma's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helus Pharma's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helus Pharma's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Helus Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Helus Pharma (HELP), the current Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
33GF Score

Get the complete analysis for HELP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.02
Price